NASDAQ:ELGX - Endologix Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.70 +0.02 (+2.94 %)
(As of 12/14/2018 04:00 PM ET)
Previous Close$0.68
Today's Range$0.67 - $0.75
52-Week Range$0.65 - $6.72
Volume1.23 million shs
Average Volume732,477 shs
Market Capitalization$67.35 million
P/E Ratio-1.46
Dividend YieldN/A
Beta0.37
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. The company also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, it offers proximal aortic extensions and limb extensions which allows physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. The company offers its EVAR products under Ovation, Powerlink System, IntuiTrak, AFX, VELA Proximal Endograft brand names; and EVAS products under the Nellix EVAS system brand name. It sells its products through direct sales force, network of agents, and independent distributors or agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.

Receive ELGX News and Ratings via Email

Sign-up to receive the latest news and ratings for ELGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ELGX
Previous Symbol
CUSIP29266S10
Phone949-595-7200

Debt

Debt-to-Equity Ratio4.38
Current Ratio1.55
Quick Ratio0.96

Price-To-Earnings

Trailing P/E Ratio-1.46
Forward P/E Ratio-1.03
P/E GrowthN/A

Sales & Book Value

Annual Sales$181.16 million
Price / Sales0.40
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.90 per share
Price / Book0.78

Profitability

EPS (Most Recent Fiscal Year)($0.48)
Net Income$-66,400,000.00
Net Margins-41.19%
Return on Equity-89.31%
Return on Assets-14.08%

Miscellaneous

Employees675
Outstanding Shares103,450,000
Market Cap$67.35 million
OptionableOptionable

Endologix (NASDAQ:ELGX) Frequently Asked Questions

What is Endologix's stock symbol?

Endologix trades on the NASDAQ under the ticker symbol "ELGX."

How were Endologix's earnings last quarter?

Endologix, Inc. (NASDAQ:ELGX) posted its earnings results on Thursday, November, 1st. The medical instruments supplier reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.24) by $0.09. The medical instruments supplier had revenue of $34.76 million for the quarter, compared to analyst estimates of $33.04 million. Endologix had a negative return on equity of 89.31% and a negative net margin of 41.19%. Endologix's revenue was down 24.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.17) EPS. View Endologix's Earnings History.

When is Endologix's next earnings date?

Endologix is scheduled to release their next quarterly earnings announcement on Wednesday, February 20th 2019. View Earnings Estimates for Endologix.

What guidance has Endologix issued on next quarter's earnings?

Endologix issued an update on its FY18 earnings guidance on Thursday, November, 1st. The company provided earnings per share guidance of ($0.91-0.87) for the period, compared to the Thomson Reuters consensus estimate of ($1.10). The company issued revenue guidance of $150-155 million, compared to the consensus revenue estimate of $151.75 million.Endologix also updated its FY 2018 guidance to $-0.91--0.87 EPS.

What price target have analysts set for ELGX?

6 analysts have issued 12-month price targets for Endologix's shares. Their predictions range from $3.00 to $4.00. On average, they expect Endologix's share price to reach $3.40 in the next twelve months. This suggests a possible upside of 385.7% from the stock's current price. View Analyst Price Targets for Endologix.

What is the consensus analysts' recommendation for Endologix?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endologix in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Endologix.

What are Wall Street analysts saying about Endologix stock?

Here are some recent quotes from research analysts about Endologix stock:
  • 1. BTIG Research analysts commented, "and Endologix reported its Q3 with few surprises given the preannouncement at the early October analyst day. Total revenue of $34.8M came in slightly above the preannounced range. Management said it felt AFX performed well in the US and Latin America, and that Ovation had a nice quarter in the US and Europe. The company reiterated its plan to go deeper into larger accounts and noted that this allowed gross margins to increase in the quarter while spend decreased ~7%. We believe ELGX offers a versatile slew of EVAR options, has a chance to be acquired, and has a shot to show premium data and/or a mortality benefit from the Nellix EVAS2 trial in 2020. We reiterate our Buy." (11/4/2018)
  • 2. According to Zacks Investment Research, "Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis. " (11/2/2018)

Has Endologix been receiving favorable news coverage?

Headlines about ELGX stock have trended somewhat negative on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Endologix earned a news impact score of -1.1 on InfoTrie's scale. They also gave media stories about the medical instruments supplier a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an effect on the stock's share price in the near future.

Who are some of Endologix's key competitors?

Who are Endologix's key executives?

Endologix's management team includes the folowing people:
  • Mr. John Onopchenko, CEO & Director (Age 59)
  • Mr. Vaseem Mahboob, Chief Financial Officer (Age 49)
  • Dr. Michael V. Chobotov, Chief Technology Officer (Age 57)
  • Mr. Robert D. Mitchell, Consultant (Age 56)
  • Mr. Jeffrey S. Brown, Chief Operations Officer

Who are Endologix's major shareholders?

Endologix's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.73%), Vanguard Group Inc (4.61%), Vanguard Group Inc. (4.61%), Redmile Group LLC (0.78%), Lombard Odier Asset Management USA Corp (0.68%) and Panagora Asset Management Inc. (0.62%). Company insiders that own Endologix stock include Christopher G Chavez, Dan Lemaitre, Guido J Neels, John D Mcdermott, Robert D Mitchell, Thomas F Zenty III and Vaseem Mahboob. View Institutional Ownership Trends for Endologix.

Which major investors are selling Endologix stock?

ELGX stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Vanguard Group Inc., Vanguard Group Inc, Lombard Odier Asset Management USA Corp and C WorldWide Group Holding A S. View Insider Buying and Selling for Endologix.

Which major investors are buying Endologix stock?

ELGX stock was purchased by a variety of institutional investors in the last quarter, including Panagora Asset Management Inc., Dimensional Fund Advisors LP, Marshall Wace LLP, Paloma Partners Management Co, Renaissance Technologies LLC, Jane Street Group LLC, BlackRock Inc. and Engineers Gate Manager LP. Company insiders that have bought Endologix stock in the last two years include Dan Lemaitre, Guido J Neels, John D Mcdermott, Robert D Mitchell, Thomas F Zenty III and Vaseem Mahboob. View Insider Buying and Selling for Endologix.

How do I buy shares of Endologix?

Shares of ELGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endologix's stock price today?

One share of ELGX stock can currently be purchased for approximately $0.70.

How big of a company is Endologix?

Endologix has a market capitalization of $67.35 million and generates $181.16 million in revenue each year. The medical instruments supplier earns $-66,400,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. Endologix employs 675 workers across the globe.

What is Endologix's official website?

The official website for Endologix is http://www.endologix.com.

How can I contact Endologix?

Endologix's mailing address is 2 MUSICK, IRVINE CA, 92618. The medical instruments supplier can be reached via phone at 949-595-7200 or via email at [email protected]


MarketBeat Community Rating for Endologix (NASDAQ ELGX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  383 (Vote Outperform)
Underperform Votes:  375 (Vote Underperform)
Total Votes:  758
MarketBeat's community ratings are surveys of what our community members think about Endologix and other stocks. Vote "Outperform" if you believe ELGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2018 by MarketBeat.com Staff

Featured Article: Liquidity

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel